Comparison 1. Oral amoxicillin versus placebo after previous treatment with ceftriaxone for disseminated Lyme disease.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptoms (patient‐rated VAS, scale 0 to 100, higher worse) in all participants (definite and possible Lyme disease)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 3 months	1	145	Mean Difference (IV, Fixed, 95% CI)	4.20 [3.39, 5.01]
1.2 6 months	1	145	Mean Difference (IV, Fixed, 95% CI)	‐0.5 [‐1.38, 0.38]
1.3 12 months	1	145	Mean Difference (IV, Fixed, 95% CI)	0.60 [‐0.21, 1.41]
2 Symptoms (investigator‐rated VAS, scale 0 to 100 higher worse) in all participants (definite and possible Lyme disease)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 3 months	1	145	Mean Difference (IV, Fixed, 95% CI)	0.5 [‐0.28, 1.28]
2.2 6 months	1	145	Mean Difference (IV, Fixed, 95% CI)	‐2.40 [‐3.18, ‐1.62]
2.3 12 months	1	145	Mean Difference (IV, Fixed, 95% CI)	‐0.40 [‐1.13, 0.33]
3 Improvement of symptoms (excellent or good on investigator VAS) (12 months) in participants with definite Lyme disease	1	107	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.93, 1.21]
4 Adverse events (12 months) in all participants (definite and possible Lyme disease)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 Serious adverse events	1	145	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 Diarrhea	1	145	Risk Ratio (M‐H, Fixed, 95% CI)	3.70 [1.29, 10.61]